R. Villanueva Vázquez

Individualization of treatment strategies

Adela Fernández Ortega, Laura Jolis López, Gemma Viñas Villaró, 2011, Advances in therapy.

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

L. Chow, A. Bardia, F. Cardoso, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

L. Chow, A. Bardia, N. Harbeck, 2018, The Lancet. Oncology.

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Miguel Martín, J. R. De la Haba-Rodríguez, S. González-Santiago, 2022, Breast.

[Cancer and cardiovascular risk].

P. Armario, R. Villanueva Vázquez, P. Blanch Gràcia, 2021, Hipertension y riesgo vascular.